In addition to presenting data at ESMO positioning its PD1 as potentially the standard of care in a new indication, Incyte thinks it has an important new drug in its CDK2 inhibitor
Bicycle Therapeutics CEO Kevin Lee highlights the company's data at the 2024 ESMO Congress
The founder of Entos Pharmaceuticals describes trying to design a delivery vehicle that's better than AAV and LNPs by harnessing fusogens
Previewing the 2024 ESMO Congress with oncology watcher Bertrand Delsuc
HSBC's Rajesh Kumar joins BiotechTV for Analyst Thursdays and talks PD-1xVEGF, obesity, European conglomerates, and more
Merck KGaA's head of global R&D and CMO gives an overview of the company's programs and its appetite for business development
Biotech expert Dirk Haussecker shares his opinion on the various emerging technology platforms in genetic medicine
London's Epsilogen completed a £12.5 million Series B expansion this week to take its IgE based folate receptor alpha program into a phase 1b study
The Co-CEOs of Summit Therapeutics discuss the ivonescimab vs Keytruda data that was presented at the 2024 World Conference on Lung Cancer
Berlin based T-knife Therapeutics is carrying on the tradition of German leadership in TCR based technologies in oncology
Andreas Eckert, founder of Eckert & Ziegler, is an expert in radio isotopes and how they are used in medicine. A subsidiary, Pentixapharm, is about to be spun off into is own public company
BioVenture VoiCes Episode 1: Venrock's Bryan Roberts
Travere's FILSPARI earned a conversion of its accelerated approval for IgA nephropathy into a full approval, a decision that came with an expanded label
The CEO of Marseille based ImCheck Therapeutics on targeting butyrophilin to modulate innate and adaptive immunity
Innate Pharma's Founder & CEO gives an overview of the company's programs and discusses Marseille's strengths in immunology
Paris Saclay Cancer Cluster is designed to support entrepreneurs and create an innovation ecosystem of oncology R&D right at Gustave Roussy
Paris based Coave Therapeutics is conjugating ligands onto vector surfaces to improve targeting and delivery - it is attracting partner and investor interest
With a partnership with Intellia already in place, France's SparingVision aims to be a world leader in gene therapies and gene editing for ocular diseases
Paris based Enterome has an IO approach that is founded on learnings from how the gut interacts with the immune system
Checking in with Imvax ahead of key P2b data in glioblastoma next year of its personalized treatment that is delivered via implantable biodiffusion chambers
.png){kind=logo}
